Rare Disease Report

American Society of Clinical Oncology 2017 | Page 2

At ASCO 2017, ArQule, Inc. announced that data from a trial with ARQ 087 exhibits significant clinical benefit to iiCCA patients housing FGFR2 fusions.
New data concludes that pediatric and young adult patients saw clinically meaningful quality of life improvements at 3 and 6 months after CTL019 therapy.
New data concludes that the incidence of MDS and AML in ovarian and breast cancer patients was higher in patients exposed to DNA damaging agents.
Dr Warsame noted 4 themes when it came to the 'cost of care' conversations: 1) drug costs, 2) disability, 3) medical bills, and 4) insurance coverage.
Acute myeloid leukemia (AML) generally occurs in older patients, and the older the patient, the more likely he or she will have comorbidities, such as diabetes, that can impact treatment.
Of the 318 survivors surveyed, 167 (53%) reported fear of cancer recurrence.
Two studies observed that aerobic activity, massage, yoga, and strength training significantly reduced disease burden using the MPN-SAF TSS scale.
Patients with uncontrolled PV have an increased risk of cardiovascular complications such as stroke, pulmonary embolism, deep vein thrombosis and heart attack.
Of the 4 patients give triple therapy, 3 obtained complete remission of the rare skin cancer.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.